Related Experiment Video
Updated: Jul 5, 2025

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
Published on: February 23, 2024
Phomopsterone B Alleviates Liver Fibrosis through mTOR-Mediated Autophagy and Apoptosis Pathway
Mei-Lin Peng1,2,3, Li-Jie Zhang1, Yan Luo1
1State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmacy, Guizhou Medical University, Guian New District, Guiyang 550004, China.
Abstract:
Liver fibrosis is the initial pathological process of many chronic liver diseases. Targeting hepatic stellate cell (HSC) activation is an available strategy for the therapy of liver fibrosis. We aimed to explore the anti-liver fibrosis activity and potential mechanism of phomopsterone B (PB) in human HSCs. The results showed that PB effectively attenuated the proliferation of TGF-β1-stimulated LX-2 cells in a concentration-dependent manner at doses of 1, 2, and 4 μM. Quantitative real-time PCR and Western blot assays displayed that PB significantly reduced the expression levels of α-SMA and collagen I/III. AO/EB and Hoechst33342 staining and flow cytometry assays exhibited that PB promoted the cells' apoptosis. Meanwhile, PB diminished the number of autophagic vesicles and vacuolated structures, and the LC3B fluorescent spots indicated that PB could effectively inhibit the accretion of autophagosomes in LX-2 cells. Moreover, rapamycin and MHY1485 were utilized to further investigate the effect of mTOR in autophagy and apoptosis. The results demonstrated that PB regulated autophagy and apoptosis via the mTOR-dependent pathway in LX-2 cells. In summary, this is the first evidence that PB effectively alleviates liver fibrosis in TGF-β1-stimulated LX-2 cells, and PB may be a promising candidate for the prevention of liver fibrosis.
Insights
Phomopsterone B (PB) effectively reduces liver fibrosis by inhibiting hepatic stellate cell proliferation and promoting apoptosis. This compound targets the mTOR pathway, offering a potential new therapy for liver fibrosis.
Area of Science:
- Pharmacology
- Hepatology
- Cell Biology
Background:
- Liver fibrosis is a key pathological process in chronic liver diseases.
- Targeting hepatic stellate cell (HSC) activation is a therapeutic strategy for liver fibrosis.
- Phomopsterone B (PB) is a compound with potential therapeutic applications.
Purpose of the Study:
- To investigate the anti-fibrotic activity of phomopsterone B (PB) in human hepatic stellate cells (HSCs).
- To elucidate the underlying mechanism of PB's action in liver fibrosis.
- To explore PB's effects on HSC proliferation, apoptosis, and autophagy.
Main Methods:
- Human HSCs (LX-2 cells) were stimulated with TGF-β1.
- PB treatment at various concentrations (1, 2, 4 μM).
- Quantitative real-time PCR, Western blot, AO/EB staining, Hoechst33342 staining, flow cytometry, and assessment of autophagy markers (LC3B).
- Investigation of the mTOR pathway using rapamycin and MHY1485.
Main Results:
- PB significantly attenuated TGF-β1-induced HSC proliferation in a dose-dependent manner.
- PB reduced the expression of fibrosis markers α-SMA and collagen I/III.
- PB induced apoptosis and inhibited autophagy in HSCs.
- PB's regulation of autophagy and apoptosis was mediated through the mTOR-dependent pathway.
Conclusions:
- Phomopsterone B (PB) demonstrates significant anti-fibrotic effects in TGF-β1-stimulated human HSCs.
- PB alleviates liver fibrosis by inhibiting HSC proliferation, promoting apoptosis, and modulating autophagy via the mTOR pathway.
- PB represents a promising therapeutic candidate for the prevention and treatment of liver fibrosis.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
The Intrinsic Apoptotic Pathway

